Intimation of the outcome of the Board Meeting held today i.e. August 07, 2026

Novartis India Limited August 07, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub: Outcome of the Meeting of the Board of Directors of Novartis India Limited (“the Company”) held on Friday, August 07, 2026. Dear Sir/ Madam, Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) read with the relevant circulars issued by SEBI (‘SEBI Circular’), we hereby inform that the Board of Directors (‘Board’) of the Company in their Meeting held today i.e. Friday, August 07, 2026, inter-alia have considered and approved the following: 1. adoption of new set of Articles of Association of the Company inter-alia, to align them with the provisions of Table F of Schedule I of the Companies Act, 2013, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. 2. adoption of the “Employee Stock Option Plan 2026”, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. 3. termination of the Distribution and Promotion Agreement dated February 11, 2022, entered by the Company with Dr. Reddy’s Laboratories Limited (DRL). The brief details of the same are attached as Annexure I. 4. Notice of 78th Annual General Meeting of the Members of the Company. The said Meeting commenced at 06:50 P.M. (IST) and concluded at 07.08 P.M. (IST). The above is for your information and the same is also available on the website of the Company i.e. www.nilpharma.co.in Thank you. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited Yours sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer A60291 Encl.: as above. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited Disclosure in terms of SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 26, 2026, for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Annexure I Sr. Particulars Details a) Name of parties to the agreement Novartis India Limited (NIL) and Dr. Reddy’s Laboratories Limited (DRL) b) Nature of the agreement Termination agreement to the distribution and promotion agreement dated February 11, 2022 (“DRL Agreement”) executed between the Company and Dr. Reddy’s Laboratories Limited (“DRL”), pursuant to which DRL had been granted the exclusive and non- transferable right to promote, distribute and sell certain products specified in the DRL Agreement. c) Date of execution of the agreement The termination agreement has been executed between the Company and DRL on August 07, 2026. The effective date of termination of the Agreement shall be September 30, 2026. d) Reasons of termination and impact thereof Pursuant to the termination of the DRL Agreement, the Company is to re-acquire exclusivity and secure market access for the products in respect of which DRL was granted exclusive and non-transferable right to promote, distribute and sell under the DRL Agreement. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in